Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Joong Won Park, Richard S. Finn, Jun Suk Kim, Mark Karwal, Ruby K. Li, Fuad Ismail, Melanie Thomas, Rosemarie Harris, Christine Baudelet, Ian Walters, Jean Luc Raoul

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.

Original languageEnglish
Pages (from-to)1973-1983
Number of pages11
JournalClinical Cancer Research
Volume17
Issue number7
DOIs
Publication statusPublished - 1 Apr 2011

Fingerprint

Disease-Free Survival
Hepatocellular Carcinoma
Survival Rate
Therapeutics
Safety
Survival
Fibroblast Growth Factors
Advisory Committees
Vascular Endothelial Growth Factor A
Fatigue
Diarrhea
Research Design
brivanib
Hypertension
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. / Park, Joong Won; Finn, Richard S.; Kim, Jun Suk; Karwal, Mark; Li, Ruby K.; Ismail, Fuad; Thomas, Melanie; Harris, Rosemarie; Baudelet, Christine; Walters, Ian; Raoul, Jean Luc.

In: Clinical Cancer Research, Vol. 17, No. 7, 01.04.2011, p. 1973-1983.

Research output: Contribution to journalArticle

Park, JW, Finn, RS, Kim, JS, Karwal, M, Li, RK, Ismail, F, Thomas, M, Harris, R, Baudelet, C, Walters, I & Raoul, JL 2011, 'Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma', Clinical Cancer Research, vol. 17, no. 7, pp. 1973-1983. https://doi.org/10.1158/1078-0432.CCR-10-2011
Park, Joong Won ; Finn, Richard S. ; Kim, Jun Suk ; Karwal, Mark ; Li, Ruby K. ; Ismail, Fuad ; Thomas, Melanie ; Harris, Rosemarie ; Baudelet, Christine ; Walters, Ian ; Raoul, Jean Luc. / Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 7. pp. 1973-1983.
@article{cc95aba33ec04d4b87f7f3704ebe13f5,
title = "Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma",
abstract = "Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95{\%} CI) was 18.2{\%} (9.1{\%}-30.9{\%}). Median progression-free survival (95{\%} CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95{\%} CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.",
author = "Park, {Joong Won} and Finn, {Richard S.} and Kim, {Jun Suk} and Mark Karwal and Li, {Ruby K.} and Fuad Ismail and Melanie Thomas and Rosemarie Harris and Christine Baudelet and Ian Walters and Raoul, {Jean Luc}",
year = "2011",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2011",
language = "English",
volume = "17",
pages = "1973--1983",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

AU - Park, Joong Won

AU - Finn, Richard S.

AU - Kim, Jun Suk

AU - Karwal, Mark

AU - Li, Ruby K.

AU - Ismail, Fuad

AU - Thomas, Melanie

AU - Harris, Rosemarie

AU - Baudelet, Christine

AU - Walters, Ian

AU - Raoul, Jean Luc

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.

AB - Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease ≥ 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC.

UR - http://www.scopus.com/inward/record.url?scp=79953325932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953325932&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2011

DO - 10.1158/1078-0432.CCR-10-2011

M3 - Article

C2 - 21349999

AN - SCOPUS:79953325932

VL - 17

SP - 1973

EP - 1983

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -